Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Pembrolizumab
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms innovaTIL-04
  • Sponsors Iovance Biotherapeutics

    • Most Recent Events

    • 28 Feb 2023 According to an Iovance Biotherapeutics media release, additional patients began enrolling to support a BLA in cervical cancer following progression on or after chemotherapy and pembrolizumab.
    • 16 Aug 2022 Planned number of patients changed from 138 to 189.
    • 16 Aug 2022 Planned End Date changed from 1 Dec 2026 to 1 Dec 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top